It is anticipated that the products, once approved, would be manufactured at Amerigen’s SFDA and US FDA approved finished dose plant in Suzhou, China, with marketing and sales undertaken either by a Chinese affiliate of VIWA or a third party.
Jack Ye, managing director of VIWA Pharmaceutical Company, said: "Combining Amerigen’s development capabilities, manufacturing assets and access to products from Western markets with VIWA’s access to API’s and regulatory expertise in China should enable the joint venture to rapidly build up its product portfolio. This in turn will help accelerate VIWA’s strategic thrust into the commercialization of finished pharmaceutical products in China."
John Lowry, president and CEO of Amerigen Pharmaceuticals, said: "The formation of this joint venture marks a first step by Amerigen to bring high quality and locally manufactured branded generic products to the Chinese market and, in the process, establish an Amerigen brand in China. We anticipate that additional collaborations will be established to further this strategy."
In addition, Amerigen Pharmaceuticals and the Shanghai Fosun Omni Pharmaceutical have signed a collaboration agreement to develop generic oral controlled release products.
Under the terms of the agreement, Fosun Omni will use its formulation expertise to develop products for Amerigen to commercialize in the US and other territories. On signing the agreement, Fosun Omni received an up-front fee with respect to the first product and is eligible for additional product-specific development milestones and royalties on any commercialized products.
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.